![]() |
Name |
2,6,6-Trimethyloctane
|
Molecular Formula | C11H24 | |
IUPAC Name* |
2,6,6-trimethyloctane
|
|
SMILES |
CCC(C)(C)CCCC(C)C
|
|
InChI |
InChI=1S/C11H24/c1-6-11(4,5)9-7-8-10(2)3/h10H,6-9H2,1-5H3
|
|
InChIKey |
RUPXAIGHLDMSOL-UHFFFAOYSA-N
|
|
Synonyms |
2,6,6-Trimethyloctane; Octane, 2,6,6-trimethyl-; 54166-32-4; 2,6,6-Trimethyloctane #; LMFA11000684
|
|
CAS | NA | |
PubChem CID | 551285 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 156.31 | ALogp: | 5.4 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 11 | QED Weighted: | 0.535 |
Caco-2 Permeability: | -4.341 | MDCK Permeability: | 0.00001300 |
Pgp-inhibitor: | 0.021 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.665 |
30% Bioavailability (F30%): | 0.839 |
Blood-Brain-Barrier Penetration (BBB): | 0.639 | Plasma Protein Binding (PPB): | 97.21% |
Volume Distribution (VD): | 2.441 | Fu: | 3.77% |
CYP1A2-inhibitor: | 0.431 | CYP1A2-substrate: | 0.857 |
CYP2C19-inhibitor: | 0.592 | CYP2C19-substrate: | 0.935 |
CYP2C9-inhibitor: | 0.467 | CYP2C9-substrate: | 0.964 |
CYP2D6-inhibitor: | 0.022 | CYP2D6-substrate: | 0.238 |
CYP3A4-inhibitor: | 0.138 | CYP3A4-substrate: | 0.201 |
Clearance (CL): | 6.381 | Half-life (T1/2): | 0.181 |
hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.022 |
Drug-inuced Liver Injury (DILI): | 0.046 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.061 | Maximum Recommended Daily Dose: | 0.024 |
Skin Sensitization: | 0.375 | Carcinogencity: | 0.072 |
Eye Corrosion: | 0.991 | Eye Irritation: | 0.973 |
Respiratory Toxicity: | 0.492 |